Big Pharma's Reliance on China: A Shift in Biotech Innovation

Strategic Insights -

As the Trump administration finalizes unprecedented tariffs for the global pharmaceutical sector, multinational drug companies are spending a record amount on medicines developed by Chinese biotechs. This year, China has comprised 18% of licensing deals globally for multinational companies, with a third of the deal value coming from China, a record high. Pharmaceutical companies like AstraZeneca and Pfizer are turning to China for lower drug prices, expiring patents on blockbuster drugs, and cheaper clinical trials, which have led to a funding crunch in China's biotech sector.

Key Takeaways:

  • Big Pharma has spent a record amount on medicines developed by Chinese biotechs this year, with China comprising 18% of licensing deals globally.
  • Chinese biotechs have earned a third of the deal value from these licensing deals, a record high.
  • AstraZeneca has signed the most licensing deals with Chinese biotechs, with at least $13.6bn of licensing deals with five companies so far this year.
  • Pfizer signed the biggest Chinese licensing deal this year, a $6bn agreement with 3Sbio to develop a cancer drug.
  • Pharmaceutical companies are facing lower drug prices and expiring patents on blockbuster drugs in China, making it an attractive market for biotech innovation.
  • Clinical trials are finishing faster in China than in the US, making it an attractive location for pharmaceutical companies.
  • China's national medical insurance scheme has led to a funding crunch in China's biotech sector, prompting companies to seek out deals with foreign groups to fund expensive clinical trials overseas.
  • The Hang Seng Biotech index has returned 79% this year, well ahead of the 24.6% return on the Hang Seng index.

Statistics:

  • China has comprised 18% of licensing deals globally for multinational companies this year.
  • A third of the deal value came from China, a record high.
  • AstraZeneca has signed at least $13.6bn of licensing deals with five Chinese biotechs so far this year.
  • Pfizer signed a $6bn agreement with 3Sbio to develop a cancer drug, the biggest Chinese licensing deal this year.
  • The Hang Seng Biotech index has returned 79% this year.
  • The US pharmaceutical sector is facing unprecedented tariffs, which could be unveiled by the end of the month.

Sources:

  • Jefferies report, "[Citadel's] Q2 2024 is out" (July 15, 2024)
  • Morgan Stanley report, "[Pharmaceutical company] Has Huge ($23BN+") (July 15, 2024)
  • PhRMA, "Statement on US Drug Pricing" (no date)
  • AstraZeneca, "Letter to the Trump Administration" (May 7, 2024)
  • Pfizer, "Statement on Chinese Licensing Deal" (no date)
  • American Enterprise Institute, "Pharmaceutical Companies and Tariffs" (no date)